Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats

Toxicology and Applied Pharmacology

Volumn 183, Issue 2, 2002, Pages 108-116

  Slim, Rabih M ^a   Robertson, Donald G ^a   Albassam, Mudher ^a   Reily, Michael D ^a   Robosky, Lora ^a   Dethloff, Lloyd A ^a  

^a PFIZER INC   (United States)

Author keywords

Dexamethasone; Metabonomics; NMR; PDE inhibitor; Vasculitis

Indexed keywords

4 PYRIDINECARBOXAMIDE(3,4,6,7 TETRAHYDRO 9 METHYL 4 OXO 1 PHENYLPYRROLO[3,2,1 JK][1,4]BENZODIAZEPIN 3 YL); ANTIINFLAMMATORY AGENT; DEXAMETHASONE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEEDING; CONTROLLED STUDY; CYTOLYSIS; DISEASE ASSOCIATION; DRUG EFFECT; EDEMA; FEEDING; FEMALE; INFLAMMATORY INFILTRATE; LIVER BLOOD VESSEL; LYMPHOCYTE; MESENTERY BLOOD VESSEL; MUSCLE ATROPHY; MUSCLE NECROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRINCIPAL COMPONENT ANALYSIS; RAT; SMOOTH MUSCLE; URINALYSIS; VASCULAR LESION; VASCULAR NECROSIS;

RATTUS NORVEGICUS;

EID: 0036406930     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-008X(02)99465-2     Document Type: Article

References (18)

1. Albassam, M. A., Smith, G. S., and Macallum, G. E. (1998). Arteriopathy induced by an adenosine agonist-antihypertensive in monkeys. Toxicol. Pathol. 26, 375-380.
2. Albassam, M. A., Metz, A. L., Gragtmans, N. J., King, L. M., Macallum, G. E., Hallak, H., and McGuire, E. J. (1999). Coronary arteriopathy in monkeys following administration of CI-1020, an endothelin A receptor antagonist. Toxicol. Pathol. 27, 156-164.
3. Anthony, M. L., Sweatman, B. C., Bedell, C. R., Lindon, J. C., and Nicholson, J. K. (1994). Pattern recognition classification of the site of nephrotoxicity based on metabolic data derived from proton nuclear magnetic resonance spectra of urine. Mol. Pharmacol. 46, 199-211.
4. Balasz, T., and Bloom, S. (1982). Cardiotoxicity of adrenergic bronchodilator and vasodilating antihypertensive drugs. In Cardiovascular Toxicology (E. W. van Stee, Ed.), pp. 199-220. Raven Press, New York.
5. Beckwith-Hall, B. M., Nicholson, J. K., Nicholls, A. W., Foxall, P. J. D., Lindon, J. C., Connor, S. C., Abdi, M., Connelly, J., and Holmes, E. (1998). Nuclear magnetic resonance spectroscopic and principle component analysis investigations into biochemical effects of three model hepatotoxins. Chem. Res. Toxicol. 11, 260-272.
6. Bugelski, P. J., Vockley, C. M., Sowinski, J. M., Arena, E., Berkowitz, B. A., and Morgan, D. G. (1989). Ultrastructure of an arterial lesion induced in rats by fenoldopam mesylate, a dopaminergic vasodilator. Br. J. Exp. Pathol. 70, 153-165.
7. Dethloff, L. A., Pegg, D. G., and Metz, A. L. (1999). Preclinical toxicity studies of phosphodiesterase IV inhibitor CI-1018 in rats. Toxicol. Sci. 48 (1S), 1502a.
8. El-Deredy, W. (1997). Pattern recognition approaches in biomedical and clinical magnetic resonance spectroscopy: A review. NMR Biomed. 10, 99 -124.
9. Holmes, E., Nicholson, J. K., Bonner, F. W., Sweatman, B. C., Beddell, C. R., Lindon, J. C., and Rahr, E. (1992). Mapping the biochemical trajectory of nephrotoxicity by pattern recognition of NMR urinalysis. NMR Biomed. 5, 368-372.
10. Holmes, E., Nicholson, J. K., Nicholls, A. W., Lindon, J. C., Connor S. C., Polley, S., and Connelly, J. (1998). The identification of novel biomarkers of renal toxicity using automatic data reduction techniques and PCA of proton NMR spectra of urine. Chemomet. Intel. Lab. Syst. 44, 245-255.
11. Holmes, E., and Shockcor, J. P. (2000). Accelerated toxicity screening using NMR and pattern recognition-based methods. Curr. Opin. Drug Discovery Dev. 3, 72-78.
12. Joseph, E. C., Rees, J. A., and Dayan, A. D. (1996). Mesenteric arteriopathy in the rat induced by phosphodiesterase III inhibitors: An investigation of morphological, ultrastructural, and hemodynamic changes. Toxicol. Pathol. 24, 436-450.
13. Joseph, E. C., Mesfin, G., and Kern, W. D. (1997). Pathogenesis of arterial lesions caused by vasoactive compounds in laboratory animals. In Cardiovascular Toxicology (S. P. Bishop and W. D. Kern, Eds.), pp. 279-306. Elsevier, New York.
14. Larson, J. L., Pino, M. V., Geiger, L. E., and Simeone, C. R. (1996). The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol. Toxicol. 78, 44-49.
15. Moore, P. M. (1995). Neurological manifestation of vasculitis: Update on immunopathogenic mechanisms and clinical features. Ann. Neurol. 37, S131-S141.
16. Nicholson, J. K., Lindon, J. C., and Holmes, E. (1999). "Metabonomics": Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181-1189.
17. Robertson, D. G., Reily, M. D., Sigler, R. E., Wells, D. F., Paterson, D. A., and Braden, T. K. (2000). Metabonomics: Evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol. Sci. 57, 326-337.
18. Robertson, D. G., Reily, H. D., Albassam, M., and Dethloff, L. A. (2001). Metabonomic assessment of vasculitis on rats. Cardiovasc. Toxicol. 1, 7-19.